• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

相似文献

1
Understanding the cross-resistance of oseltamivir to H1N1 and H5N1 influenza A neuraminidase mutations using multidimensional computational analyses.利用多维计算分析理解奥司他韦对甲型H1N1和H5N1流感神经氨酸酶突变的交叉耐药性。
Drug Des Devel Ther. 2015 Jul 31;9:4137-54. doi: 10.2147/DDDT.S81934. eCollection 2015.
2
Infiltration of water molecules into the oseltamivir-binding site of H274Y neuraminidase mutant causes resistance to oseltamivir.水分子渗透进入 H274Y 神经氨酸酶突变体的奥司他韦结合位点导致对奥司他韦的耐药性。
J Chem Inf Model. 2009 Dec;49(12):2735-41. doi: 10.1021/ci900348n.
3
Source of oseltamivir resistance in avian influenza H5N1 virus with the H274Y mutation.具有 H274Y 突变的禽流感 H5N1 病毒中奥司他韦耐药的来源。
Amino Acids. 2009 Oct;37(4):725-32. doi: 10.1007/s00726-008-0201-z. Epub 2008 Nov 12.
4
Theoretical studies on the susceptibility of oseltamivir against variants of 2009 A/H1N1 influenza neuraminidase.奥司他韦对 2009 年 A/H1N1 流感神经氨酸酶变异体敏感性的理论研究。
J Chem Inf Model. 2012 Oct 22;52(10):2715-29. doi: 10.1021/ci300375k. Epub 2012 Oct 2.
5
Comment on "Another look at the molecular mechanism of the resistance of H5N1 influenza A virus neuraminidase (NA) to oseltamivir (OTV)".关于《再探甲型H5N1流感病毒神经氨酸酶(NA)对奥司他韦(OTV)耐药性的分子机制》的评论
Biophys Chem. 2009 Apr;141(1):131-2; author reply 133. doi: 10.1016/j.bpc.2009.01.009. Epub 2009 Feb 2.
6
Mutation-induced loop opening and energetics for binding of tamiflu to influenza N8 neuraminidase.突变诱导的环打开和结合流感 N8 神经氨酸酶的能量变化。
J Phys Chem B. 2012 May 31;116(21):6137-49. doi: 10.1021/jp3022612. Epub 2012 May 17.
7
Insights into susceptibility of antiviral drugs against the E119G mutant of 2009 influenza A (H1N1) neuraminidase by molecular dynamics simulations and free energy calculations.通过分子动力学模拟和自由能计算深入了解 2009 年甲型流感(H1N1)神经氨酸酶 E119G 突变体对抗病毒药物的敏感性。
Antiviral Res. 2013 Nov;100(2):356-64. doi: 10.1016/j.antiviral.2013.09.006. Epub 2013 Sep 19.
8
Crystal structures of oseltamivir-resistant influenza virus neuraminidase mutants.耐奥司他韦流感病毒神经氨酸酶突变体的晶体结构
Nature. 2008 Jun 26;453(7199):1258-61. doi: 10.1038/nature06956. Epub 2008 May 14.
9
Profiling and characterization of influenza virus N1 strains potentially resistant to multiple neuraminidase inhibitors.对可能对多种神经氨酸酶抑制剂具有耐药性的流感病毒 N1 株进行分析和鉴定。
J Virol. 2015 Jan;89(1):287-99. doi: 10.1128/JVI.02485-14. Epub 2014 Oct 15.
10
Discovery of a non-zwitterionic oseltamivir analogue as a potent influenza a neuraminidase inhibitor.发现一种非两性离子奥司他韦类似物作为有效的流感 A 神经氨酸酶抑制剂。
Eur J Med Chem. 2020 Aug 15;200:112423. doi: 10.1016/j.ejmech.2020.112423. Epub 2020 May 12.

引用本文的文献

1
Role of ROCK signaling in virus replication.ROCK 信号通路在病毒复制中的作用。
Virus Res. 2023 May;329:199105. doi: 10.1016/j.virusres.2023.199105. Epub 2023 Apr 1.
2
Broad-spectrum antiviral activity of Spatholobus suberectus Dunn against SARS-CoV-2, SARS-CoV-1, H5N1, and other enveloped viruses.鸡血藤对 SARS-CoV-2、SARS-CoV-1、H5N1 及其他包膜病毒具有广谱抗病毒活性。
Phytother Res. 2022 Aug;36(8):3232-3247. doi: 10.1002/ptr.7452.
3
Repurposing of existing antibiotics for the treatment of diabetes mellitus.现有抗生素重新用于治疗糖尿病。

本文引用的文献

1
Routine Microsecond Molecular Dynamics Simulations with AMBER on GPUs. 2. Explicit Solvent Particle Mesh Ewald.使用AMBER在GPU上进行常规微秒级分子动力学模拟。2. 显式溶剂粒子网格埃瓦尔德方法
J Chem Theory Comput. 2013 Sep 10;9(9):3878-88. doi: 10.1021/ct400314y. Epub 2013 Aug 20.
2
Global update on the susceptibility of human influenza viruses to neuraminidase inhibitors, 2012-2013.2012 - 2013年全球人类流感病毒对神经氨酸酶抑制剂敏感性的最新情况
Antiviral Res. 2014 Oct;110:31-41. doi: 10.1016/j.antiviral.2014.07.001. Epub 2014 Jul 17.
3
Assessing the performance of MM/PBSA and MM/GBSA methods. 4. Accuracies of MM/PBSA and MM/GBSA methodologies evaluated by various simulation protocols using PDBbind data set.
In Silico Pharmacol. 2022 Mar 5;10(1):4. doi: 10.1007/s40203-021-00118-6. eCollection 2022.
4
Antivirals Targeting the Neuraminidase.抗神经氨酸酶药物。
Cold Spring Harb Perspect Med. 2022 Jan 4;12(1):a038455. doi: 10.1101/cshperspect.a038455.
5
Inhibition of sialidase activity as a therapeutic approach.抑制唾液酸酶活性作为一种治疗方法。
Drug Des Devel Ther. 2018 Oct 10;12:3431-3437. doi: 10.2147/DDDT.S176220. eCollection 2018.
6
Combined computational and experimental studies of molecular interactions of albuterol sulfate with bovine serum albumin for pulmonary drug nanoparticles.硫酸沙丁胺醇与牛血清白蛋白在肺部药物纳米颗粒中的分子相互作用的计算与实验联合研究
Drug Des Devel Ther. 2016 Sep 15;10:2973-2987. doi: 10.2147/DDDT.S114663. eCollection 2016.
7
The significance of naturally occurring neuraminidase quasispecies of H5N1 avian influenza virus on resistance to oseltamivir: a point of concern.H5N1禽流感病毒自然产生的神经氨酸酶准种对奥司他韦耐药性的意义:一个值得关注的问题。
J Gen Virol. 2016 Jun;97(6):1311-1323. doi: 10.1099/jgv.0.000444. Epub 2016 Mar 2.
评估MM/PBSA和MM/GBSA方法的性能。4. 使用PDBbind数据集通过各种模拟协议评估MM/PBSA和MM/GBSA方法的准确性。
Phys Chem Chem Phys. 2014 Aug 21;16(31):16719-29. doi: 10.1039/c4cp01388c.
4
Bird to human transmission biases and vaccine escape mutants in H5N1 infections.H5N1感染中的禽传人传播偏向性和疫苗逃逸突变体
PLoS One. 2014 Jul 2;9(7):e100754. doi: 10.1371/journal.pone.0100754. eCollection 2014.
5
Demographic and clinical predictors of mortality from highly pathogenic avian influenza A (H5N1) virus infection: CART analysis of international cases.高致病性甲型禽流感(H5N1)病毒感染所致死亡的人口统计学和临床预测因素:国际病例的分类与回归树分析
PLoS One. 2014 Mar 25;9(3):e91630. doi: 10.1371/journal.pone.0091630. eCollection 2014.
6
A community cluster of influenza A(H1N1)pdm09 virus exhibiting cross-resistance to oseltamivir and peramivir in Japan, November to December 2013.日本 2013 年 11 月至 12 月出现的具有交叉耐药性的甲型 H1N1pdm09 流感病毒社区集群
Euro Surveill. 2014 Jan 9;19(1):20666. doi: 10.2807/1560-7917.es2014.19.1.20666.
7
A conformational restriction in the influenza A virus neuraminidase binding site by R152 results in a combinational effect of I222T and H274Y on oseltamivir resistance.甲型流感病毒神经氨酸酶结合位点中由R152引起的构象限制导致I222T和H274Y对奥司他韦耐药产生联合效应。
Antimicrob Agents Chemother. 2014;58(3):1639-45. doi: 10.1128/AAC.01848-13. Epub 2013 Dec 23.
8
Mutation effects of neuraminidases and their docking with ligands: a molecular dynamics and free energy calculation study.神经氨酸酶的突变效应及其与配体的对接:分子动力学和自由能计算研究。
J Comput Aided Mol Des. 2013 Nov;27(11):935-50. doi: 10.1007/s10822-013-9691-1. Epub 2013 Nov 12.
9
Analysis and assay of oseltamivir-resistant mutants of influenza neuraminidase via direct observation of drug unbinding and rebinding in simulation.通过模拟中直接观察药物的解结合和再结合来分析和检测流感神经氨酸酶的奥司他韦耐药突变体。
Biochemistry. 2013 Nov 12;52(45):8150-64. doi: 10.1021/bi400754t. Epub 2013 Oct 30.
10
Exploitation of the catalytic site and 150 cavity for design of influenza A neuraminidase inhibitors.利用催化位点和 150 腔进行流感 A 神经氨酸酶抑制剂的设计。
J Org Chem. 2013 Nov 1;78(21):10867-77. doi: 10.1021/jo401854w. Epub 2013 Oct 16.

利用多维计算分析理解奥司他韦对甲型H1N1和H5N1流感神经氨酸酶突变的交叉耐药性。

Understanding the cross-resistance of oseltamivir to H1N1 and H5N1 influenza A neuraminidase mutations using multidimensional computational analyses.

作者信息

Singh Ashona, Soliman Mahmoud E

机构信息

School of Health Sciences, University of KwaZulu-Natal, Westville, Durban, South Africa.

出版信息

Drug Des Devel Ther. 2015 Jul 31;9:4137-54. doi: 10.2147/DDDT.S81934. eCollection 2015.

DOI:10.2147/DDDT.S81934
PMID:26257512
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC4527369/
Abstract

This study embarks on a comprehensive description of the conformational contributions to resistance of neuraminidase (N1) in H1N1 and H5N1 to oseltamivir, using comparative multiple molecular dynamic simulations. The available data with regard to elucidation of the mechanism of resistance as a result of mutations in H1N1 and H5N1 neuraminidases is not well established. Enhanced post-dynamic analysis, such as principal component analysis, solvent accessible surface area, free binding energy calculations, and radius of gyration were performed to gain a precise insight into the binding mode and origin of resistance of oseltamivir in H1N1 and H5N1 mutants. Three significant features reflecting resistance in the presence of mutations H274Y and I222K, of the protein complexed with the inhibitor are: reduced flexibility of the α-carbon backbone; an improved ΔEele of 15 (kcal/mol) for H1N1 coupled with an increase in ΔGsol (13 kcal/mol) from wild-type to mutation; a low binding affinity in comparison with the wild-type of ~2 (kcal/mol) and ~7 (kcal/mol) with respect to each mutation for the H5N1 systems; and reduced hydrophobicity of the overall surface structure due to an impaired hydrogen bonding network. We believe the results of this study will ultimately provide a useful insight into the structural landscape of neuraminidase-associated binding of oseltamivir. Furthermore, the results can be used in the design and development of potent inhibitors of neuraminidases.

摘要

本研究采用比较多分子动力学模拟方法,全面描述了H1N1和H5N1中神经氨酸酶(N1)对奥司他韦耐药性的构象贡献。关于H1N1和H5N1神经氨酸酶突变导致耐药机制的现有数据尚未完全确立。进行了增强的动力学后分析,如主成分分析、溶剂可及表面积、自由结合能计算和回转半径分析,以深入了解奥司他韦在H1N1和H5N1突变体中的结合模式和耐药起源。在与抑制剂结合的蛋白质中,H274Y和I222K突变存在时反映耐药性的三个显著特征是:α-碳骨架的灵活性降低;H1N1的ΔEele提高约15(kcal/mol),同时从野生型到突变体的ΔGsol增加(约13 kcal/mol);与野生型相比,H5N1系统中每个突变的结合亲和力较低,分别约为2(kcal/mol)和7(kcal/mol);以及由于氢键网络受损导致整体表面结构的疏水性降低。我们相信,本研究结果最终将为奥司他韦与神经氨酸酶相关结合的结构格局提供有益的见解。此外,这些结果可用于设计和开发有效的神经氨酸酶抑制剂。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/e50f/4527369/20e05120abbb/dddt-9-4137Fig10.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/e50f/4527369/0f7449d1c33c/dddt-9-4137Fig1.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/e50f/4527369/b17812864903/dddt-9-4137Fig2.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/e50f/4527369/21cfecce7dc9/dddt-9-4137Fig3.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/e50f/4527369/fe41844c6e0a/dddt-9-4137Fig4.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/e50f/4527369/7f7270bc695f/dddt-9-4137Fig5.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/e50f/4527369/5e3a0abc2665/dddt-9-4137Fig6.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/e50f/4527369/4dc783e64f5f/dddt-9-4137Fig7.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/e50f/4527369/914e4319f634/dddt-9-4137Fig8.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/e50f/4527369/1c988f9fbbbd/dddt-9-4137Fig9.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/e50f/4527369/20e05120abbb/dddt-9-4137Fig10.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/e50f/4527369/0f7449d1c33c/dddt-9-4137Fig1.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/e50f/4527369/b17812864903/dddt-9-4137Fig2.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/e50f/4527369/21cfecce7dc9/dddt-9-4137Fig3.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/e50f/4527369/fe41844c6e0a/dddt-9-4137Fig4.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/e50f/4527369/7f7270bc695f/dddt-9-4137Fig5.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/e50f/4527369/5e3a0abc2665/dddt-9-4137Fig6.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/e50f/4527369/4dc783e64f5f/dddt-9-4137Fig7.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/e50f/4527369/914e4319f634/dddt-9-4137Fig8.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/e50f/4527369/1c988f9fbbbd/dddt-9-4137Fig9.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/e50f/4527369/20e05120abbb/dddt-9-4137Fig10.jpg